IN2014MN01781A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01781A IN2014MN01781A IN1781MUN2014A IN2014MN01781A IN 2014MN01781 A IN2014MN01781 A IN 2014MN01781A IN 1781MUN2014 A IN1781MUN2014 A IN 1781MUN2014A IN 2014MN01781 A IN2014MN01781 A IN 2014MN01781A
- Authority
- IN
- India
- Prior art keywords
- cdim
- binding proteins
- cells
- well
- diagnostic assays
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 abstract 4
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 4
- 108091008324 binding proteins Proteins 0.000 abstract 4
- 238000003556 assay Methods 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000025171 antigen binding proteins Human genes 0.000 abstract 1
- 108091000831 antigen binding proteins Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 230000000779 depleting effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261633330P | 2012-02-08 | 2012-02-08 | |
| PCT/US2013/025430 WO2013120012A2 (en) | 2012-02-08 | 2013-02-08 | Cdim binding proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01781A true IN2014MN01781A (enrdf_load_stackoverflow) | 2015-07-03 |
Family
ID=48045015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1781MUN2014 IN2014MN01781A (enrdf_load_stackoverflow) | 2012-02-08 | 2013-02-08 |
Country Status (14)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2922830A1 (en) | 2013-09-05 | 2015-04-16 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
| CN113072644A (zh) * | 2013-12-17 | 2021-07-06 | 埃姆医疗有限公司 | 抵抗骨髓增生障碍或淋巴组织增生障碍的手段和方法 |
| DK3105250T3 (da) | 2014-02-10 | 2020-09-28 | Igm Biosciences Inc | Multispecifikke iga-bindingsmolekyler |
| US10400038B2 (en) | 2014-04-03 | 2019-09-03 | Igm Biosciences, Inc. | Modified J-chain |
| HUE051013T2 (hu) | 2015-01-20 | 2021-01-28 | Igm Biosciences Inc | Tumor nekrózis faktor (TNF) szupercsalád receptor kötõ molekulák és ezek alkalmazása |
| CN115093479A (zh) * | 2015-03-04 | 2022-09-23 | Igm生物科学股份有限公司 | Cd20结合分子及其用途 |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| JP6811723B2 (ja) | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法 |
| ES2819870T3 (es) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Moléculas de unión con cadena J modificada |
| PT3355913T (pt) | 2015-09-30 | 2024-12-18 | Igm Biosciences Inc | Moléculas de ligação com cadeia j modificada |
| KR102343742B1 (ko) | 2016-05-09 | 2021-12-24 | 아이쥐엠 바이오사이언스 인코포레이티드 | 항-pd-l1 항체 |
| WO2018033841A1 (en) | 2016-08-15 | 2018-02-22 | Novartis Ag | Regimens and methods of treating multiple sclerosis using ofatumumab |
| EP3579866A4 (en) * | 2017-02-08 | 2020-12-09 | Dragonfly Therapeutics, Inc. | HEAVY CHAIN VARIABLE ANTIBODY DOMAINS WITH NKG2D RECEPTOR AIMING |
| FI3579848T3 (fi) | 2017-02-08 | 2025-01-22 | Dragonfly Therapeutics Inc | Monispesifisiä sitovia proteiineja luonnollisten tappajasolujen aktivointiin ja niiden terapeuttisia käyttöjä syövän hoitoon |
| KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| MX2019011986A (es) | 2017-04-07 | 2019-11-07 | Igm Biosciences Inc | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. |
| JP7690286B2 (ja) | 2018-02-08 | 2025-06-10 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ受容体を標的とする抗体可変ドメイン |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| JP7376490B2 (ja) | 2018-03-01 | 2023-11-08 | アイジーエム バイオサイエンシズ インコーポレイテッド | ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異 |
| PE20211860A1 (es) | 2018-08-08 | 2021-09-21 | Dragonfly Therapeutics Inc | Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2020033664A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| BR112021009373A2 (pt) * | 2018-11-16 | 2021-08-17 | Memorial Sloan Kettering Cancer Center | anticorpos para mucina-16 e métodos de uso dos mesmos |
| BR112022002780A2 (pt) | 2019-08-15 | 2022-05-10 | Igm Biosciences Inc | Moléculas de ligação multiméricas imunoestimulatórias |
| BR112022021884A2 (pt) | 2020-05-06 | 2022-12-20 | Dragonfly Therapeutics Inc | Proteínas que se ligam a nkg2d, cd16 e clec12a |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| CN114181318B (zh) * | 2021-11-08 | 2023-08-01 | 四川大学 | 一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5099069A (en) | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5246692A (en) | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5460785A (en) | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
| US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
| ES2165851T3 (es) | 1991-11-25 | 2002-04-01 | Enzon Inc | Proteinas multivalentes que se unen a antigenos. |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US6312691B1 (en) | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| US6962979B1 (en) | 1995-03-14 | 2005-11-08 | Cohesion Technologies, Inc. | Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6680335B2 (en) | 1998-09-28 | 2004-01-20 | Sugen, Inc. | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds |
| AU780052B2 (en) | 1999-09-17 | 2005-02-24 | Abbott Gmbh & Co. Kg | Pyrazolopyrimidines as therapeutic agents |
| US20020028178A1 (en) | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
| CA2476625A1 (en) * | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| US7485297B2 (en) * | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
| MXPA06005104A (es) | 2003-11-05 | 2007-01-25 | Palingen Inc | Citotoxicidad de celulas b aumentada en anticuerpos de enlace a cdim. |
| US20120237441A9 (en) * | 2003-11-05 | 2012-09-20 | Bhat Neelima M | Enhanced b cell cytotoxicity of cdim binding antibody |
| CN101098889A (zh) * | 2004-11-05 | 2008-01-02 | 盘林京有限公司 | 抗体导致的细胞膜损伤 |
| AU2005333155B2 (en) * | 2005-03-14 | 2011-11-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies against Hendra and Nipah viruses |
| CA2623016A1 (en) * | 2005-09-19 | 2007-03-29 | Palingen, Inc. | Treatment of b cell diseases using anti-germline antibody binding agents |
| CN101808661A (zh) * | 2007-04-02 | 2010-08-18 | 安进弗里蒙特公司 | 抗IgE抗体 |
-
2013
- 2013-02-08 MX MX2014009628A patent/MX363819B/es active IP Right Grant
- 2013-02-08 BR BR112014019459-9A patent/BR112014019459B1/pt active IP Right Grant
- 2013-02-08 CN CN201380008515.XA patent/CN104254544B/zh active Active
- 2013-02-08 CA CA2863714A patent/CA2863714C/en active Active
- 2013-02-08 ES ES13713588T patent/ES2735289T3/es active Active
- 2013-02-08 IN IN1781MUN2014 patent/IN2014MN01781A/en unknown
- 2013-02-08 US US13/763,398 patent/US9409976B2/en active Active
- 2013-02-08 TW TW102105337A patent/TWI606064B/zh active
- 2013-02-08 AU AU2013200903A patent/AU2013200903B2/en active Active
- 2013-02-08 JP JP2014556751A patent/JP6335796B2/ja active Active
- 2013-02-08 WO PCT/US2013/025430 patent/WO2013120012A2/en not_active Ceased
- 2013-02-08 DK DK13713588.5T patent/DK2812356T3/da active
- 2013-02-08 KR KR1020147025110A patent/KR102102111B1/ko active Active
- 2013-02-08 EP EP13713588.5A patent/EP2812356B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2812356A2 (en) | 2014-12-17 |
| US20140044739A1 (en) | 2014-02-13 |
| BR112014019459A8 (pt) | 2023-01-10 |
| WO2013120012A2 (en) | 2013-08-15 |
| CA2863714C (en) | 2022-07-05 |
| BR112014019459A2 (pt) | 2017-06-27 |
| EP2812356B1 (en) | 2019-03-27 |
| JP6335796B2 (ja) | 2018-06-06 |
| MX2014009628A (es) | 2015-03-19 |
| AU2013200903B2 (en) | 2015-05-14 |
| CA2863714A1 (en) | 2013-08-15 |
| CN104254544A (zh) | 2014-12-31 |
| AU2013200903A1 (en) | 2013-08-22 |
| JP2015511817A (ja) | 2015-04-23 |
| KR20150001728A (ko) | 2015-01-06 |
| WO2013120012A3 (en) | 2013-11-07 |
| HK1205136A1 (en) | 2015-12-11 |
| CN104254544B (zh) | 2017-04-26 |
| BR112014019459B1 (pt) | 2023-04-18 |
| TWI606064B (zh) | 2017-11-21 |
| DK2812356T3 (da) | 2019-07-08 |
| KR102102111B1 (ko) | 2020-04-20 |
| ES2735289T3 (es) | 2019-12-17 |
| US9409976B2 (en) | 2016-08-09 |
| MX363819B (es) | 2019-04-03 |
| TW201345921A (zh) | 2013-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01781A (enrdf_load_stackoverflow) | ||
| PH12019500439A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| MX349096B (es) | Anticuerpos anti-pd-l1 y sus usos. | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| PH12015501092A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
| PH12018500640A1 (en) | Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi) | |
| PH12017501583B1 (en) | Novel proteins specific for cd137 | |
| MY177970A (en) | Bcma (cd269/tnfrsf17) -binding proteins | |
| BR112013019975A2 (pt) | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" | |
| BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
| IN2014CN03936A (enrdf_load_stackoverflow) | ||
| UA107706C2 (uk) | Апоптоз-індукуючий засіб для лікування раку й імунних і аутоімунних захворювань | |
| PH12015500084A1 (en) | Rspo3 binding agents and uses thereof | |
| PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| NZ701370A (en) | Il-6 binding molecules | |
| EA201370155A1 (ru) | Композиция и способ лечения рака | |
| BR112012014345A2 (pt) | peptídeos tmem22 e vacinas incluindo os mesmos | |
| WO2013040547A3 (en) | Compounds and methods of immunization with tumor antigens | |
| TN2013000265A1 (en) | Anti-cd38 antibodies |